Niraparib

Generic Name
Niraparib
Brand Names
Zejula
Drug Type
Small Molecule
Chemical Formula
C19H20N4O
CAS Number
1038915-60-4
Unique Ingredient Identifier
HMC2H89N35
Background

Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal can...

Indication

Niraparib is indicated for the maintenance treatment of adult patients with advanced or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.
...

Associated Conditions
Advanced Epithelial Ovarian Cancer, Advanced Primary Peritoneal Carcinoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Advanced Fallopian Tubes Cancer
Associated Therapies
Maintenance therapy
Clinical Trials
Related News

A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

First Posted Date
2021-08-05
Last Posted Date
2024-06-03
Lead Sponsor
Artios Pharma Ltd
Target Recruit Count
390
Registration Number
NCT04991480
Locations
🇺🇸

Yale School of Medicine, New Haven, Connecticut, United States

🇺🇸

Florida Cancer Specialists, Orlando, Florida, United States

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 5 locations

Real-world Study of Niraparib Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer

Not yet recruiting
Conditions
Epithelial Ovarian Cancer
First Posted Date
2021-08-02
Last Posted Date
2021-08-02
Lead Sponsor
Ling-Ying Wu
Target Recruit Count
300
Registration Number
NCT04986371

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

First Posted Date
2021-07-01
Last Posted Date
2024-06-06
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
200
Registration Number
NCT04947254
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers

First Posted Date
2021-06-15
Last Posted Date
2024-11-19
Lead Sponsor
Joseph Caster, Ph.D., M.D.
Target Recruit Count
38
Registration Number
NCT04926324
Locations
🇺🇸

Holden Comprehensive Cancer Center at the University of Iowa, Iowa City, Iowa, United States

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Phase 3
Active, not recruiting
Conditions
Neoplasms, Breast
Interventions
Drug: Niraparib
Drug: Placebo
First Posted Date
2021-06-07
Last Posted Date
2024-07-22
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
43
Registration Number
NCT04915755
Locations
🇬🇧

GSK Investigational Site, Wigan., United Kingdom

Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma

First Posted Date
2021-05-20
Last Posted Date
2022-06-29
Lead Sponsor
Walid Shaib, MD
Registration Number
NCT04895046

Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer

First Posted Date
2021-04-08
Last Posted Date
2023-11-15
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
32
Registration Number
NCT04837209
Locations
🇺🇸

Sibley Memorial Hospital, Washington, District of Columbia, United States

🇺🇸

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

and more 1 locations

Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months

First Posted Date
2021-04-01
Last Posted Date
2024-12-05
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Target Recruit Count
13
Registration Number
NCT04826198
Locations
🇫🇷

CHU Jean Minjoz, Besançon, Besancon, France

🇫🇷

Hospices civils de Lyon(CHU Lyon Sud), Pierre-Bénite, Lyon, France

🇫🇷

Institut de Cancérologie de l'Ouest - St Herblain, Saint-Herblain, Nantes, France

and more 3 locations

Real-life Use of Niraparib in a Patient Access Program in Norway

First Posted Date
2021-03-08
Last Posted Date
2021-03-08
Lead Sponsor
Kristina Lindemann
Target Recruit Count
106
Registration Number
NCT04785716
Locations
🇳🇴

Oslo University Hospital (OUH), Oslo, Norway

Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab

First Posted Date
2021-03-03
Last Posted Date
2024-03-26
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Target Recruit Count
51
Registration Number
NCT04779151
Locations
🇫🇷

Gustave Roussy, Villejuif, Val De Marne, France

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy